2 recruiting, 2 unknown, 1 not yet recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Unknown 1 |
Follow Jun Zhang, MD, PhD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) Cabozantinib, Atezolizumab - Lung Cancer, NSCLC Stage IV | Phase 2 | Not yet recruiting | Jun Zhang, MD, PhD | 40 | 2024-12-01 | 2024-05-08 |
| Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC Standard of care immune checkpoint inhbitors - Lung Cancer, NSCLC | Recruiting | Jun Zhang, MD, PhD | 25 | 2022-07-21 | 2024-02-23 | |
| Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy Ipatasertib - NSCLC Stage IV, NSCLC Stage IIIB | Phase 2 | Unknown | Jun Zhang, MD, PhD | 60 | 2021-09-14 | 2023-11-07 |
| Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients NSCLC, Stage III, Locally Advanced Lung Carcinoma | Recruiting | Jun Zhang, MD, PhD | 44 | 2021-04-12 | 2024-05-08 | |
| Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC) Microbiome - NSCLC Stage IV, NSCLC, Recurrent | Unknown | Jun Zhang, MD, PhD | 46 | 2020-07-29 | 2023-12-11 |
Carcinoma, Non-Small-Cell Lung (5) · Lung Neoplasms (2) · Recurrence (1)
Microbiota (1) · atezolizumab (1) · cabozantinib (1) · ipatasertib (1)
United States (5)